# Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract

> **NCT02254421** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 60 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infection

## Interventions

- **DRUG:** Presatovir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02254421
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-31
- **Primary completion:** 2017-04-17
- **Final completion:** 2017-04-17
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02254421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02254421, "Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT02254421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*